Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Letter to the Editor Regarding "National Trends for Reoperation in Older Patients with Glioblastoma".

Reiner AS, Goldman DA, Diamond EL, DeAngelis LM, Tabar V, Panageas KS.

World Neurosurg. 2018 Sep;117:466. doi: 10.1016/j.wneu.2018.04.156. No abstract available.

PMID:
30149428
2.

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O.

J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. Epub 2018 Aug 6.

3.

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J, Cohen-Aubart F, Rodriguez-Galindo C, Allen C, Whitlock JA, Weitzman S, McClain KL, Haroche J, Diamond EL.

Blood. 2018 Jun 28;131(26):2877-2890. doi: 10.1182/blood-2018-03-839753. Epub 2018 May 2. Review.

PMID:
29720485
4.

Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E.

J Clin Oncol. 2018 Jun 10;36(17):1702-1709. doi: 10.1200/JCO.2017.76.9992. Epub 2018 Apr 23.

PMID:
29683790
5.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

6.

Associations between Mild Cognitive Dysfunction and End-of-Life Outcomes in Patients with Advanced Cancer.

Kurita K, Reid MC, Siegler EL, Diamond EL, Prigerson HG.

J Palliat Med. 2018 Apr;21(4):536-540. doi: 10.1089/jpm.2017.0385. Epub 2018 Jan 3.

PMID:
29298104
7.

The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.

Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR, Busam KJ, Travis WD, Diamond EL, Dogan A.

Mod Pathol. 2018 Apr;31(4):581-597. doi: 10.1038/modpathol.2017.160. Epub 2017 Dec 1.

PMID:
29192649
8.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.

9.

Prognostic awareness and communication preferences among caregivers of patients with malignant glioma.

Applebaum AJ, Buda K, Kryza-Lacombe M, Buthorn JJ, Walker R, Shaffer KM, D'Agostino TA, Diamond EL.

Psychooncology. 2018 Mar;27(3):817-823. doi: 10.1002/pon.4581. Epub 2017 Dec 19.

PMID:
29125714
10.

Erdheim-Chester disease: the "targeted" revolution.

Vaglio A, Diamond EL.

Blood. 2017 Sep 14;130(11):1282-1284. doi: 10.1182/blood-2017-07-795054. No abstract available.

11.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

12.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

13.

Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma.

Diamond EL, Prigerson HG, Correa DC, Reiner A, Panageas K, Kryza-Lacombe M, Buthorn J, Neil EC, Miller AM, DeAngelis LM, Applebaum AJ.

Neuro Oncol. 2017 Oct 19;19(11):1532-1541. doi: 10.1093/neuonc/nox117.

14.

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.

Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, Hélias-Rodzewicz Z, Terrones N, Ozkaya N, Dogan A, Rampal R, Urbain F, Le Fèvre L, Diamond EL, Park CY, Papo T, Charlotte F, Gorochov G, Taly V, Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF.

Blood. 2017 Jul 13;130(2):176-180. doi: 10.1182/blood-2016-12-757377. Epub 2017 May 31.

15.

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.

Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M.

Blood. 2017 Jul 13;130(2):167-175. doi: 10.1182/blood-2016-12-757823. Epub 2017 May 16.

16.

Frequency and Risk Factors for Live Discharge from Hospice.

Russell D, Diamond EL, Lauder B, Dignam RR, Dowding DW, Peng TR, Prigerson HG, Bowles KH.

J Am Geriatr Soc. 2017 Aug;65(8):1726-1732. doi: 10.1111/jgs.14859. Epub 2017 Mar 13.

PMID:
28295138
17.

Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma.

Diamond EL, Panageas KS, Dallara A, Pollock A, Applebaum AJ, Carver AC, Pentsova E, DeAngelis LM, Prigerson HG.

J Pain Symptom Manage. 2017 Feb;53(2):257-264. doi: 10.1016/j.jpainsymman.2016.09.008. Epub 2016 Nov 1.

18.

Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease.

Diamond EL, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Brody L, Arcila M, Bowers C, Fluchel M.

Blood. 2016 Oct 6;128(14):1896-1898. doi: 10.1182/blood-2016-06-725143. Epub 2016 Aug 17. No abstract available.

19.

Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease.

Diamond EL, Hatzoglou V, Patel S, Abdel-Wahab O, Rampal R, Hyman DM, Holodny AI, Raj A.

Orphanet J Rare Dis. 2016 Aug 2;11(1):109. doi: 10.1186/s13023-016-0490-3.

20.

Histiocytic neoplasms in the era of personalized genomic medicine.

Durham BH, Diamond EL, Abdel-Wahab O.

Curr Opin Hematol. 2016 Jul;23(4):416-25. doi: 10.1097/MOH.0000000000000256. Review.

21.

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM; Histiocyte Society.

Blood. 2016 Jun 2;127(22):2672-81. doi: 10.1182/blood-2016-01-690636. Epub 2016 Mar 10. Review.

22.

Nonenhancing Leptomeningeal Metastases: Imaging Characteristics and Potential Causative Factors.

Hatzoglou V, Karimi S, Diamond EL, Lis E, Krol G, Holodny AI, Young RJ.

Neurohospitalist. 2016 Jan;6(1):24-8. doi: 10.1177/1941874415591702.

23.

High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system.

Curry RC, Faivre G, Akkari L, Joyce JA, Lin O, Rosenblum M, Diamond EL, Fisher R, Omuro A.

Leuk Lymphoma. 2016 Aug;57(8):1961-4. doi: 10.3109/10428194.2015.1120867. Epub 2016 Jan 4. No abstract available.

PMID:
26727454
24.

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Héritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O.

Cancer Discov. 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-15-0913. Epub 2015 Nov 13.

25.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J.

N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. Erratum in: N Engl J Med. 2018 Oct 18;379(16):1585.

26.

Rates and risks for late referral to hospice in patients with primary malignant brain tumors.

Diamond EL, Russell D, Kryza-Lacombe M, Bowles KH, Applebaum AJ, Dennis J, DeAngelis LM, Prigerson HG.

Neuro Oncol. 2016 Jan;18(1):78-86. doi: 10.1093/neuonc/nov156. Epub 2015 Aug 9.

27.

Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"?

Huse JT, Diamond EL, Wang L, Rosenblum MK.

Acta Neuropathol. 2015 Jan;129(1):151-3. doi: 10.1007/s00401-014-1359-y. Epub 2014 Oct 31. No abstract available.

PMID:
25359109
28.

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.

Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O.

Cancer Discov. 2015 Jan;5(1):64-71. doi: 10.1158/2159-8290.CD-14-0742. Epub 2014 Oct 16.

29.

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, Trad S, Nizard P, Donadieu J, Taly V, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2014 Nov 6;124(19):3016-9. doi: 10.1182/blood-2014-04-570937. Epub 2014 Aug 22.

30.

Prognostic awareness and communication of prognostic information in malignant glioma: a systematic review.

Diamond EL, Corner GW, De Rosa A, Breitbart W, Applebaum AJ.

J Neurooncol. 2014 Sep;119(2):227-34. doi: 10.1007/s11060-014-1487-1. Epub 2014 May 30. Review.

31.

Visualization of orbital involvement of Erdheim-Chester disease on PET/CT.

Beylergil V, Carrasquillo JA, Hyman DM, Diamond EL.

Clin Nucl Med. 2014 Jul;39(7):660-1. doi: 10.1097/RLU.0000000000000452.

PMID:
24873784
32.

Giant cell arteritis presenting with bilateral orbital inflammatory disease and enhancing superficial temporal arteries.

Mitchell JR, Krashin-Bichler I, Rosenblum M, Diamond EL, Dinkin MJ.

Pract Neurol. 2014 Dec;14(6):446-7. doi: 10.1136/practneurol-2014-000834. Epub 2014 May 22. No abstract available.

33.

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, Arnaud L, Haroche J.

Blood. 2014 Jul 24;124(4):483-92. doi: 10.1182/blood-2014-03-561381. Epub 2014 May 21.

34.

Temporal lobe meningioma with ipsilateral herpes simplex encephalitis.

Diamond EL, Hatzoglou V, Santomasso B, Rosenblum M, Pentsova E.

Neurohospitalist. 2014 Jan;4(1):42-3. doi: 10.1177/1941874413489154. No abstract available.

35.

Detection of an NRAS mutation in Erdheim-Chester disease.

Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya-Feldstein J, Hyman DM, Rosenblum M.

Blood. 2013 Aug 8;122(6):1089-91. doi: 10.1182/blood-2013-02-482984. No abstract available.

36.

Transient aqueductal occlusion in intracerebral haemorrhage.

Diamond EL, Kimchi EY, Shankar GM, Silverman SB.

Pract Neurol. 2012 Dec;12(6):388-9. doi: 10.1136/practneurol-2011-000174. No abstract available.

PMID:
23144305
37.

Widespread intracerebral metastases from prostate adenocarcinoma.

Mackay DD, Diamond EL, Klein JP.

Pract Neurol. 2012 Aug;12(4):257-8. doi: 10.1136/practneurol-2012-000273. No abstract available.

PMID:
22869771
38.

Minor cognitive impairments in cancer patients magnify the effect of caregiver preferences on end-of-life care.

Gao X, Prigerson HG, Diamond EL, Zhang B, Wright AA, Meyer F, Maciejewski PK.

J Pain Symptom Manage. 2013 Apr;45(4):650-9. doi: 10.1016/j.jpainsymman.2012.03.003. Epub 2012 Jul 28.

39.

Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease.

McLaren DG, Sreenivasan A, Diamond EL, Mitchell MB, Van Dijk KR, Deluca AN, O'Brien JL, Rentz DM, Sperling RA, Atri A.

Neurodegener Dis. 2012;9(4):176-86. doi: 10.1159/000335876. Epub 2012 Mar 27.

40.

Teaching NeuroImages: restricted diffusion in the corpus callosum after traumatic diffuse axonal injury.

Edlow BL, Diamond EL.

Neurology. 2010 Oct 26;75(17):e69. doi: 10.1212/WNL.0b013e3181f962d7. No abstract available.

PMID:
20975045
41.

Factor XIII deficiency related recurrent spontaneous intracerebral hemorrhage: a case and literature review.

Perez DL, Diamond EL, Castro CM, Diaz A, Buonanno F, Nogueira RG, Sheth K.

Clin Neurol Neurosurg. 2011 Feb;113(2):142-5. doi: 10.1016/j.clineuro.2010.09.003. Epub 2010 Oct 14.

PMID:
20950938
42.

Glioma stem cell signaling: therapeutic opportunities and challenges.

Dietrich J, Diamond EL, Kesari S.

Expert Rev Anticancer Ther. 2010 May;10(5):709-22. doi: 10.1586/era.09.190. Review.

PMID:
20470003
43.

Meningitis associated with sphenoid sinus encephalocoele.

Sheikh SI, Vaitkevicius H, Mez J, Diamond EL.

Pract Neurol. 2010 Feb;10(1):43-4. doi: 10.1136/jnnp.2009.200980. No abstract available.

PMID:
20130297
44.

Relationship of fMRI activation to clinical trial memory measures in Alzheimer disease.

Diamond EL, Miller S, Dickerson BC, Atri A, DePeau K, Fenstermacher E, Pihlajamäki M, Celone K, Salisbury S, Gregas M, Rentz D, Sperling RA.

Neurology. 2007 Sep 25;69(13):1331-41.

PMID:
17893294
45.

Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study.

Sperling RA, Guttmann CR, Hohol MJ, Warfield SK, Jakab M, Parente M, Diamond EL, Daffner KR, Olek MJ, Orav EJ, Kikinis R, Jolesz FA, Weiner HL.

Arch Neurol. 2001 Jan;58(1):115-21.

PMID:
11176944
46.

Prospective study of occupational asthma to laboratory animal allergens: stability of airway responsiveness to methacholine challenge for one year.

Newill CA, Eggleston PA, Prenger VL, Fish JE, Diamond EL, Wei Q, Evans R 3rd.

J Allergy Clin Immunol. 1995 Mar;95(3):707-15.

PMID:
7897154
47.

Comparative epidemiology of selected midline congenital abnormalities.

Yang P, Khoury MJ, Stewart WF, Beaty TH, Chee E, Beatty JC, Diamond EL, Gordis L.

Genet Epidemiol. 1994;11(2):141-54.

PMID:
8013895
48.

Serum micronutrients and the subsequent risk of oral and pharyngeal cancer.

Zheng W, Blot WJ, Diamond EL, Norkus EP, Spate V, Morris JS, Comstock GW.

Cancer Res. 1993 Feb 15;53(4):795-8.

49.

Characteristics of asthma mortality and morbidity in African-Americans.

Malveaux FJ, Houlihan D, Diamond EL.

J Asthma. 1993;30(6):431-7.

PMID:
8244912
50.

Risk factors for increased airway responsiveness to methacholine challenge among laboratory animal workers.

Newill CA, Prenger VL, Fish JE, Evans R 3rd, Diamond EL, Wei Q, Eggleston PA.

Am Rev Respir Dis. 1992 Dec;146(6):1494-500.

PMID:
1456566

Supplemental Content

Loading ...
Support Center